BridgeMD
New treatment option for Hepatocellular Carcinoma
Official title Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
ClinicalTrials.gov ID: NCT05842174
What this study is testing
What is Hydroxychloroquine?
Hydroxychloroquine is an investigational medicine, given as an once-daily infusion into a vein, being studied as a potential treatment for hepatocellular carcinoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemotherapeutics and then blocking the artery with embolics in order to kill tumor cells by depriving them of essential oxygen and nutrients.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Male or female, aged 18 years, meeting criteria for diagnosis of BCLC B HCC and referred to undergo TACE
- HCC measuring 3 cm in minimum transverse diameter and meets LI-RADS 5 criteria based on cross-sectional imaging as determined by a board-certified...
- Childs Pugh Turcotte A/B7, Performance Status 0
- Informed of investigational nature of this study with provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
You likely can't join if
- QT prolongation on ECG
- Retinopathy on ophthalmologic examination
- Females who are pregnant or breast feeding at the time of screening will not be eligible for this study
- a serum or urine pregnancy test will be performed in women of child-bearing potential at screening
- Prior LRT or systemic therapy to the target lesion
- Contraindication to contrast enhanced MRI or metallic implant within the liver.
See the full eligibility criteria
- Male or female, aged 18 years, meeting criteria for diagnosis of BCLC B HCC and referred to undergo TACE
- HCC measuring 3 cm in minimum transverse diameter and meets LI-RADS 5 criteria based on cross-sectional imaging as determined by a board-certified, sub-specialty trained radiologist
- Childs Pugh Turcotte A/B7, Performance Status 0
- Informed of investigational nature of this study with provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- QT prolongation on ECG
- Retinopathy on ophthalmologic examination
- Females who are pregnant or breast feeding at the time of screening will not be eligible for this study
- a serum or urine pregnancy test will be performed in women of child-bearing potential at screening
- Prior LRT or systemic therapy to the target lesion
- Contraindication to contrast enhanced MRI or metallic implant within the liver.
- HCQ allergy, porphyria, uncontrolled psoriasis, and existing retinopathy
- Lesion not amenable to biopsy based on pre-TACE imaging as determined by treating treatment radiologist
- Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study)
The study team makes the final eligibility decision.
Where it's taking place
- Philadelphia, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.